Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kala Pharmaceuticals Inc (KALA)
NASDAQ:KALA
KALA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.21 - $11.20
Previous CloseN/A
Volume15.45K
Average Volume (3M)89.31K
Market Cap
$43.98M
Enterprise Value$14.21M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Mar 27, 2025EPS Estimate
-2.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.47
Shares Outstanding6,091,182
10 Day Avg. Volume149,907
30 Day Avg. Volume89,308
Standard Deviation0.85
R-Squared0.02
Alpha0.08
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.32
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-46.91
Enterprise Value/Ebitda-0.43
Forecast
1Y Price Target
$15.00Price Target Upside121.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Kala Pharmaceuticals News
PremiumCompany Announcements
Kala Bio Advances PCED Treatment Amid Financial UpdatePremiumCompany Announcements
Kala Pharmaceuticals Board Member Mark Blumenkranz Resigns
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressPositive safety data from Cohort 1 of the CHASE trial has been reported, allowing the trial to advance to Cohort 2.
Leadership ContinuityThe Board has appointed Mr. Todd Bazemore as the interim Chief Executive Officer, ensuring leadership continuity.
Market OpportunityThere is no FDA-approved drug with a broad indication for all underlying etiologies of PCED, highlighting the potential market opportunity for KPI-012.
Bears Say
Clinical Trial RisksRisks include, but are not limited to: failure of KPI-012 in clinical trials, failure to obtain regulatory approval, and potential dilution risk.
Funding RisksManagement expects current capital together with anticipated funding under the CIRM award to fund operations into 4Q25, suggesting potential financial constraints beyond this period.
Regulatory Approval UncertaintyThe Phase 2b CHASE trial of KPI-012 could potentially serve as the first of two pivotal trials required for a Biologics License Application (BLA) submission, indicating uncertainty until further trials are completed.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KALA FAQ
What was Kala Pharmaceuticals Inc’s price range in the past 12 months?
Kala Pharmaceuticals Inc lowest stock price was $4.21 and its highest was $11.20 in the past 12 months.
What is Kala Pharmaceuticals Inc’s market cap?
Kala Pharmaceuticals Inc’s market cap is $43.98M.
When is Kala Pharmaceuticals Inc’s upcoming earnings report date?
Kala Pharmaceuticals Inc’s upcoming earnings report date is Mar 27, 2025 which is in 34 days.
How were Kala Pharmaceuticals Inc’s earnings last quarter?
Kala Pharmaceuticals Inc released its earnings results on Nov 12, 2024. The company reported -$1.93 earnings per share for the quarter, beating the consensus estimate of -$2.43 by $0.5.
Is Kala Pharmaceuticals Inc overvalued?
According to Wall Street analysts Kala Pharmaceuticals Inc’s price is currently Undervalued.
Does Kala Pharmaceuticals Inc pay dividends?
Kala Pharmaceuticals Inc does not currently pay dividends.
What is Kala Pharmaceuticals Inc’s EPS estimate?
Kala Pharmaceuticals Inc’s EPS estimate is -2.28.
How many shares outstanding does Kala Pharmaceuticals Inc have?
Kala Pharmaceuticals Inc has 6,091,182 shares outstanding.
What happened to Kala Pharmaceuticals Inc’s price movement after its last earnings report?
Kala Pharmaceuticals Inc reported an EPS of -$1.93 in its last earnings report, beating expectations of -$2.43. Following the earnings report the stock price went down -4.189%.
Which hedge fund is a major shareholder of Kala Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in KALA
---
Kala Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.00 (121.57% Upside)
$15.00 (121.57% Upside)
Insider Transactions
Bought Shares
Worth $2.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 2.2%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-4.51%
12-Months-Change
Fundamentals
Return on Equity
-430.96%
Trailing 12-Months
Asset Growth
-11.52%
Trailing 12-Months
Company Description
Kala Pharmaceuticals Inc
Kala Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Watertown, MA.
---
KALA Stock 12 Month Forecast
Average Price Target
$15.00
▲(121.57% Upside)
Technical Analysis
EyePoint Pharmaceuticals
―
Karyopharm Therapeutics
―
Aldeyra Therapeutics
―
Ocular Therapeutix
―
Best Analysts Covering KALA
1 Year
1 Year Success Rate
1/15 ratings generated profit
1 Year Average Return
-66.75%
reiterated a buy rating 9 days ago
Copying Francois Brisebois's trades and holding each position for 1 Year would result in 6.67% of your transactions generating a profit, with an average return of -66.75% per trade.
---